Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

By S. Derijcke, J. Vansteenkiste. 2009

1,470 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/e38b4845c4a603fa3a69e801fb10cc2133e666da

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Carlos L. Arteaga
2. G. Masters
3. William Pao
4. J. Engelman
5. David H. Johnson
6. P. Iyengar
7. Alexa B. Turke
8. S. Temin

Citations in the corpus

• Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition (2016, unknown): “The gene targets covered by this assay are as follows (exons): AKT1 (3), ALK (22, 23, 25), APC (16), BRAF (11, 15), CDH1 (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,12, 13, 14, 15, 16), CDKN2A (1, 2, 3), CTNNB1 (3), DDR2 (12, 13, 14, 15, 16, 17, 18), EGFR (7, 15, 18, 19, 20, 21), ERBB2 (10, 20), ESR1 (8), FB”
• Current Challenges in Cancer Treatment. (2016, background): “Actually, the genetic basis and some clinically relevant mechanisms of acquired resistance in EGFR- or ALK-mutant lung cancers have been characterized, enabling the development of selective drugs to overcome resistant clones.53 This has been done either by studying clinical samples (re-biopsies take”
• AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer (2014, unknown): “4101 (2732, 6156) 692 (193, 2478) 200 (41, 974) 30 (9, 99) 54 (ND) 461 (230, 924) NCI-H2073 (WT) PC-9 VanR (ex19del/T790M)”
• Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer (2016, unknown): “Neutropenia† 22 (8) 4 (1) 31 (23) 16 (12)”
• The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review) (2017, unknown): “This drug also targets against PI3K in solid tumors (124,125), serine/threonine kinase BRAF to treat melanoma (126-128), the receptor tyrosine kinase EGFR for lung cancer (129,130), and serine/threonine kinase mTOR for the treatment of renal tumors (131).”
• Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. (2013, background): “provement in progression-free survival (PFS) compared with chemotherapy.(2-6) The trials have all”
• First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. (2015, background): “Afatinib and gefitinib have also demonstrated efficacy in the first-line treatment of patients with EGFRmutation-positive NSCLC [12–15].”
• Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer (2010, background): “In 2009, two landmark randomized prospective Phase III studies (the Iressa Pan-Asia Study (IPASS) and WJTOG3405) showed that an EGFR TKI is superior to chemotherapy as an initial treatment for EGFR -mutant lung cance”